← Back to patent-cliff list
CAS 623-47-2
ethyl propiolate(Ethoxycarbonyl)acetylene
Codes: SELP-007, (V)101438-31-a, (III)169995-11-a,(III)169995-11-b, (II)169995-17-a, (II)169995-22-a, MAXA-037, TASE-014
Application context (from source-drug indications)
Solid tumourSelpercatinibMedullary thyroid cancerSelpercatinibNon-small cell lung cancerSelpercatinibThyroid cancerSelpercatinibBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateContraceptionDrospirenoneStomatitis, aphthousDrospirenonePremenstrual dysphoric disorderDrospirenonePremenstrual syndromeDrospirenoneDysmenorrhoeaDrospirenoneDepressionDrospirenonePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelSecondary hyperparathyroidismMaxacalcitolHyperparathyroidismMaxacalcitolBreast cancerTaselisibBladder cancerTaselisibMultiple myelomaTaselisibLung cancerTaselisibLiver cancerTaselisibCervical cancerTaselisib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Selpercatinib | Tier C — Watch / trade | 2032 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Drospirenone | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Maxacalcitol | Tier C — Watch / trade | - |
| Taselisib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile→tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate→tert-butyl 3-(5-(3-cyano-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridin-4-yl)pyridin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate→4-(6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile→6-methoxynicotinaldehyde→tert-butyl hydroxycarbamate→2,4,6-trimethylbenzenesulfonyl chloride→tert-butyl ((mesitylsulfonyl)oxy)carbamate→O-(mesitylsulfonyl)hydroxylamine→3-bromo-5-methoxypyridine→1-amino-3-bromo-5-methoxypyridin-1-ium 2,4,6-trimethylbenzenesulfonate→ethyl propiolate→ethyl 6-bromo-4-methoxypyrazolo[1,5-a]pyridine-3-carboxylate→ethyl 4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carboxylate→4-bromo-6-methoxypyrazolo[1,5-a]pyridine→4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carbaldehyde→(E)-4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carbaldehyde oxime→4-bromo-6-methoxypyrazolo[1,5-a]pyridine-3-carbonitrile→4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile→2,2-dimethyloxirane→4-bromo-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile→2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one→1-Bromo-3-methyl-2-butene→2-{2,6,6-trimethyl-4-oxobicyclo[3.1.1]hept-2-en-3-yl}acetaldehyde→2-{2,6,6-trimethyl-7-oxobicyclo[3.1.1]hept-2-en-1-yl}acetaldehyde→ethyl (2S,6R)-2,6-dihydroxy-4,10,11,11-tetramethyl-3-oxotricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→(Ethoxycarbonyl)acetylene→ethyl 5-{2,6,6-trimethyl-7-oxobicyclo[3.1.1]hept-2-en-1-yl}-4-[(trimethylsilyl)oxy]pent-2-ynoate→ethyl (6R)-3,6-dihydroxy-4,10,11,11-tetramethyltricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→ethyl (6R)-6-hydroxy-4,10,11,11-tetramethyl-3-oxotricyclo[5.3.1.0(1,6)]undeca-4,9-diene-5-carboxylate→(2S,3S,6S)-5-(hydroxymethyl)-4,10,11,11-tetramethyltricyclo[5.3.1.0(1,6)]undeca-4,9-diene-2,3,6-triol→(2S,6S,9S)-8-{[(tert-butyldimethylsilyl)oxy]methyl}-4,4,7,13,14,14-hexamethyl-3,5-dioxatetracyclo[8.3.1.0(1,9).0(2,6)]tetradeca-7,12-dien-9-ol→(2S,6S,7Z,12S)-8-{[(tert-butyldimethylsilyl)oxy]methyl}-4,4,7,13,14,14-hexamethyl-12-{[tris(propan-2-yl)silyl]oxy}-3,5-dioxatricyclo[8.3.1.0(2,6)]tetradeca-1(13),7-dien-9-one→(2S,6S,7Z,9S,10S,12S)-8-(hydroxymethyl)-4,4,7,13,14,14-hexamethyl-12-[(triisopropylsilyl)oxy]-3,5-dioxatricyclo[8.3.1.0(2,6)]tetradeca-1(13),7-diene-9,10-diol→(1S,5S,6S,7S,8S,12S,15S)-7,10,10,14,17,17-hexamethyl-6-{[(trimethylsilyl)oxy]methyl}-15-{[tris(propan-2-yl)silyl]oxy}-2,4,9,11-tetraoxatetracyclo[11.3.1.0(1,5).0(8,12)]heptadec-13-en-3-one→(1S,5S,6R,7S,8S,12S,15S)-7,10,10,14,17,17-hexamethyl-3-oxo-15-[(triisopropylsilyl)oxy]-2,4,9,11-tetraoxatetracyclo[11.3.1.0(1,5).0(8,12)]heptadec-13-ene-6-carbaldehyde→2-[(1S,5S,6R,7S,8S,9S,12S)-8,9-dihydroxy-7,11,14,14-tetramethyl-3-oxo-12-{[tris(propan-2-yl)silyl]oxy}-2,4-dioxatricyclo[8.3.1.0(1,5)]tetradec-10-en-6-yl]acetaldehyde→2-[(1S,5S,6S,7S,8S,12S)-7,11,14,14-tetramethyl-3,9-dioxo-8-[(triethylsilyl)oxy]-12-[(triisopropylsilyl)oxy]-2,4-dioxatricyclo[8.3.1.0(1,5)]tetradec-10-en-6-yl]prop-2-enal
(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→3beta-[tert-Butyl(dimethyl)silyloxy]-5beta-hydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-one→(Ethoxycarbonyl)acetylene→3-[3beta-[tert-Butyl(dimethyl)silyloxy]-5beta,17beta-dihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl]-2-propynoic acid ethyl ester→3-[3beta,5beta,17beta-Trihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl]-2-propynoic acid ethyl ester→3-[5beta,17beta-Dihydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrostan-17-yl]-2-propynoic acid ethyl ester→3-[17beta-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrost-4-en-17-yl]-2-propynoic acid ethyl ester→3-[17beta-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrost-4-en-17-yl]-2-propynoic acid
(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→(Ethoxycarbonyl)acetylene→3-[3beta,5beta,17beta-Trihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl]-2-propynoic acid ethyl ester→5beta-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3beta-(trimethylsilyloxy)androstan-17-one→3-[5beta,17beta-Dihydroxy-6beta,7beta:15beta,16beta-dimethylene-3beta-(trimethylsilyloxy)androstan-17-yl]-2-propynoic acid ethyl ester
(1aR,1bR,3S,5aR,5bS,7aS,8aS,9aS,9bS,9cR,9dR)-1b,3-Dihydroxy-5a,7a-dimethylperhydrocyclopropa[4,5]cyclopenta[1,2-a]cyclopropa[l]phenanthren-8-one→(Ethoxycarbonyl)acetylene→3-(3beta,5beta,17alpha-Trihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl)-2-propynoic acid ethyl ester→3-(3beta,5beta,17alpha-dihydroxy-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl)propionic acid ethyl ester→3-(5beta,17alpha-Dihydroxy-3-oxo-6beta,7beta:15beta,16beta-dimethyleneandrostan-17-yl)propionic acid ethyl ester→3-(5beta,17alpha-Dihydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrostan-17-yl)-2-propynoic acid ethyl ester→3-(17alpha-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrost-4-en-17-yl)-2-propynoic acid ethyl ester→3-(17alpha-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxoandrost-4-en-17-yl)propionic acid ethyl ester
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | PHOSPHINE OXIDE, [2-[3,5-BIS [[(1,1-DIMETHYLETHYL) DIMETHYLSILY]OXY]-2-METHYLENECYCLOHEXYLIDENE]ETHYL]DIPHENYL-,[3S-(1Z,3A,5B0)] Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (1S,3aR,4S,7aS)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-1H-inden-4-ol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | (1S,3aR,7aR)-1-((S)-1-(3-hydroxy-3-Methylbutoxy)ethyl)-7a-Methylhexahydro-1H-inden-4(2H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (1S,3aR,7aR)-Octahydro-7a-Methyl-1-((1S)-1-(3-Methyl-3-((triMethylsilyl)oxy)butoxy)ethyl)-4H-Inden-4-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | (Z)-2-((3S,5R)-3,5-bis((tert-butyldiMethylsilyl)oxy)-2-Methylenecyclohexylidene)ethanol Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.